DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade

DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade

Immune checkpoint inhibitor (ICI) treatment could bring long-lasting clinical benefits to patients with metastatic cancer. However, only a small proportion of patients respond to PD-1/PD-L1 blockade, so predictive biomarkers are needed. Here, based on DNA methylation profiles and the objective respo...

Full description

Bibliographic Details
Main Authors:	Gang Xue, Ze-Jia Cui, Xiong-Hui Zhou, Yue-Xing Zhu, Ying Chen, Feng-Ji Liang, Da-Nian Tang, Bing-Yang Huang, Hong-Yu Zhang, Zhi-Huang Hu, Xi-Yu Yuan, Jianghui Xiong
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-08-01
Series:	Frontiers in Genetics
Subjects:	PD-1/PD-L1 inhibition therapy objective response rate DNA methylation biomarkers Lasso model
Online Access:	https://www.frontiersin.org/article/10.3389/fgene.2019.00724/full

Similar Items

PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
by: Long Jia, et al.
Published: (2018-06-01)

Resistance Mechanism of PD-1/PD-L1 Blockade in the Cancer-Immunity Cycle
by: Zhuang Y, et al.
Published: (2020-01-01)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
by: Jing W, et al.
Published: (2016-01-01)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
by: Chen Q, et al.
Published: (2018-08-01)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
by: Chen CY, et al.
Published: (2018-07-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
by: Oliver Kepp, et al.
Published: (2019-10-01)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
by: Youhai Jiang, et al.
Published: (2020-03-01)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
by: Jin-Yu Sun, et al.
Published: (2020-08-01)

Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy
by: Yong-jun LIU, et al.
Published: (2017-06-01)

Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of <i>KRAS</i>-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8<sup>+</sup> T Cells
by: Iosune Baraibar, et al.
Published: (2020-10-01)

Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy
by: Robainas M, et al.
Published: (2017-03-01)

Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
by: Tian Tian, et al.
Published: (2021-09-01)

Triple Combination Therapy With PD-1/PD-L1, BRAF, and MEK Inhibitor for Stage III–IV Melanoma: A Systematic Review and Meta-Analysis
by: Ye Liu, et al.
Published: (2021-06-01)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
by: Feifei Teng, et al.
Published: (2020-09-01)

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
by: Daixi Ren, et al.
Published: (2020-01-01)

M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer
by: Rui Zhao, et al.
Published: (2021-01-01)

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
by: Jun Gong, et al.
Published: (2018-06-01)

Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy
by: Song Xue, et al.
Published: (2017-04-01)

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
by: C. Bryce Johnson, et al.
Published: (2018-04-01)

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy
by: Hongbo Zhang, et al.
Published: (2021-06-01)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
by: Ana Bocanegra, et al.
Published: (2020-08-01)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
by: Zijun Y. Xu-Monette, et al.
Published: (2017-12-01)

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer
by: Florus C. de Jong, et al.
Published: (2021-03-01)

PD-1 and PD-L1 correlated gene expression profiles and their association with clinical outcomes of breast cancer
by: Cui Jiang, et al.
Published: (2019-09-01)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
by: Fei Tang, et al.
Published: (2018-05-01)

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
by: Miren Zuazo, et al.
Published: (2020-11-01)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
by: Jakub Litak, et al.
Published: (2019-10-01)

Specific zinc finger‐induced methylation of PD‐L1 promoter inhibits its expression
by: Xue Li, et al.
Published: (2019-06-01)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
by: Maite Alvarez, et al.
Published: (2020-02-01)

Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
by: Ranjan Pathak, et al.
Published: (2020-12-01)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
by: Miren Zuazo, et al.
Published: (2019-07-01)

Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
by: Xiaoliang Liu, et al.
Published: (2019-08-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
by: Masaki Terabe, et al.
Published: (2017-05-01)

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
by: Yilun Wu, et al.
Published: (2019-08-01)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
by: Jian-ye Zhang, et al.
Published: (2020-05-01)

Anticancer Effect of Salvia plebeia and Its Active Compound by Improving T-Cell Activity via Blockade of PD-1/PD-L1 Interaction in Humanized PD-1 Mouse Model
by: Jang-Gi Choi, et al.
Published: (2020-11-01)

Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
by: Zuzana Macek Jilkova, et al.
Published: (2019-10-01)

PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects
by: D'Alessio A, et al.
Published: (2021-08-01)

Cannot write session to /tmp/vufind_sessions/sess_gtrei402ijdhj1k8p3t565dhvn